A Look At Cooper Companies (COO) Valuation As MyDAY Manufacturing Constraints Are Resolved

How Cooper Companies Stock Has Been Performing Recently

Cooper Companies (COO) has seen mixed share performance recently, with a 1-day return of roughly a 2% decline, a slight gain over the past week, and negative returns over the month and past 3 months.

See our latest analysis for Cooper Companies.

At a share price of $70.17, the stock has seen pressure in recent months, with a 30 day share price return of 12.51% and a 90 day share price return of 13.49% adding to a 3 year total shareholder return of 24.60%. This suggests that momentum has been fading over both shorter and longer periods.

If recent weakness in Cooper Companies has you rethinking your sector mix, it can help to compare other areas of the market using the Simply Wall St screener for 36 healthcare AI stocks

With Cooper Companies shares down over the past year and trading around $70.17, while sitting at a discount to some intrinsic and analyst estimates, investors may ask whether this represents a buying opportunity or whether expectations for future growth are already reflected in the share price.

Most Popular Narrative: 23.6% Undervalued

Cooper Companies last closed at $70.17, while the most followed narrative frames fair value at $91.80, using an 8.14% discount rate to weigh future cash flows against today’s price.

The company recently resolved its manufacturing constraints for MyDAY, its premium daily silicone hydrogel contact lens, and is now accelerating global rollout with expanded fitting sets, trial lenses, and over 30 new private label contracts. This is expected to drive substantial revenue growth and market share gains as pent-up demand is fulfilled and the premium offering captures higher margins over time.

Read the complete narrative.

Want to see what sits behind that fair value gap? The narrative leans on steady revenue expansion, rising margins, and a future earnings multiple that assumes meaningful profit compounding.

Result: Fair Value of $91.80 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this hinges on MyDAY ramping smoothly and on contact lens market growth not slowing further, as softer demand or pricing pressure could quickly challenge that undervaluation story.

Find out about the key risks to this Cooper Companies narrative.

Another Angle: Multiples Send A Different Signal

While the narrative and fair value estimate suggest Cooper Companies is undervalued, the current P/E of 34.1x is higher than both the US Medical Equipment industry at 26.6x and peer average at 22.3x, and above a fair ratio of 28.2x. That kind of premium can point to valuation risk if earnings or sentiment slip.

For investors, the key question is whether the MyDAY ramp and earnings forecasts justify paying above both peers and the fair ratio, or whether it makes sense to wait for the numbers or the price to move closer together.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this mix of optimism and caution leaves you undecided, take a closer look at the data yourself and move quickly to shape your own view with 3 key rewards.

Looking for more investment ideas?

Do not stop at one company. If you want a stronger watchlist, use targeted stock lists that surface clear opportunities based on quality, value, and resilience.

• Target quality at a discount by scanning companies that look attractively priced with solid fundamentals using the 59 high quality undervalued stocks.
• Strengthen your income stream by checking companies offering higher yields that may support steadier payouts through the 13 dividend fortresses.
• Prioritise resilience by focusing on companies with robust finances and cleaner risk profiles through the 68 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com